UY30670A1 - Nuevos compuestos de pirazolina, composiciones conteniéndolos y aplicaciones. - Google Patents

Nuevos compuestos de pirazolina, composiciones conteniéndolos y aplicaciones.

Info

Publication number
UY30670A1
UY30670A1 UY30670A UY30670A UY30670A1 UY 30670 A1 UY30670 A1 UY 30670A1 UY 30670 A UY30670 A UY 30670A UY 30670 A UY30670 A UY 30670A UY 30670 A1 UY30670 A1 UY 30670A1
Authority
UY
Uruguay
Prior art keywords
new
applications
compositions containing
compounds
pirazoline
Prior art date
Application number
UY30670A
Other languages
English (en)
Inventor
Rico Joseph Gerace
Reitz David Bruce
Mahoney William Matthew
Long Scott Allen
Hockerman Landis Susan
Xiangyang Chen
Barbieri Graciela
Marvin Jay Meyers
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY30670A1 publication Critical patent/UY30670A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invencion está dirigida a nuevos compuestos pirimidina bicíclicos de Formula (I) o a una forma o composicion de ésta como inhibidores de las interacciones de ATP-protein quinasa, donde los sustituyentes en cada lado del enlace doble iminometilo en la Formula (I) pueden estar en la configuracion E o Z; y donde R1, R2, R3 y R4 son tal como se definen aquí.
UY30670A 2006-10-31 2007-10-29 Nuevos compuestos de pirazolina, composiciones conteniéndolos y aplicaciones. UY30670A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86360606P 2006-10-31 2006-10-31

Publications (1)

Publication Number Publication Date
UY30670A1 true UY30670A1 (es) 2008-05-31

Family

ID=39027523

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30670A UY30670A1 (es) 2006-10-31 2007-10-29 Nuevos compuestos de pirazolina, composiciones conteniéndolos y aplicaciones.

Country Status (40)

Country Link
US (3) US7781428B2 (es)
EP (1) EP2089367B1 (es)
JP (1) JP4977760B2 (es)
KR (1) KR101107800B1 (es)
CN (1) CN101541757A (es)
AP (1) AP2527A (es)
AR (1) AR063529A1 (es)
AT (1) ATE537151T1 (es)
AU (1) AU2007315884B2 (es)
BR (1) BRPI0717937A2 (es)
CA (1) CA2667966C (es)
CL (1) CL2007003154A1 (es)
CO (1) CO6160307A2 (es)
CR (1) CR10725A (es)
CU (1) CU23779B7 (es)
CY (1) CY1112311T1 (es)
DK (1) DK2089367T3 (es)
EA (1) EA016370B1 (es)
ES (1) ES2375877T3 (es)
GE (1) GEP20115239B (es)
GT (1) GT200700096A (es)
HN (1) HN2007000437A (es)
HR (1) HRP20120078T1 (es)
IL (1) IL198241A0 (es)
MA (1) MA30821B1 (es)
MX (1) MX2009004662A (es)
MY (1) MY145795A (es)
NI (1) NI200900071A (es)
NO (1) NO20091741L (es)
NZ (1) NZ575923A (es)
PE (1) PE20081472A1 (es)
PL (1) PL2089367T3 (es)
PT (1) PT2089367E (es)
RS (2) RS52203B (es)
SI (1) SI2089367T1 (es)
TN (1) TN2009000160A1 (es)
TW (1) TWI357327B (es)
UA (1) UA92670C2 (es)
UY (1) UY30670A1 (es)
WO (1) WO2008053300A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091057A1 (es) 2007-12-19 2009-07-20 Lilly Co Eli Antagonistas del receptor mineralcorticoide y metodos de uso
MX336881B (es) * 2009-10-29 2016-02-04 Bristol Myers Squibb Co Compuestos heterociclicos triciclicos.
EP3238781B1 (en) 2010-05-10 2019-07-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
EP2569310A1 (en) 2010-05-11 2013-03-20 Pfizer Inc Morpholine compounds as mineralocorticoid receptor antagonists
JP6180930B2 (ja) 2010-06-16 2017-08-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 創傷治癒過程における再上皮化を刺激するための方法及び組成物
CN102372710A (zh) * 2010-08-18 2012-03-14 山东轩竹医药科技有限公司 作为盐皮质激素受体拮抗剂的并环类化合物
US10172907B2 (en) 2010-10-05 2019-01-08 Nova Southeastern University Compositions comprising β-arrestin 1 and methods of use thereof for therapeutic modulation of aldosterone levels in heart disease
WO2016001631A1 (en) 2014-06-30 2016-01-07 Astrazeneca Ab Benzoxazinone amides as mineralocorticoid receptor modulators
JP6835836B2 (ja) 2015-10-13 2021-02-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 脈絡膜血管新生の処置のための方法及び医薬組成物
US20190262363A1 (en) 2016-07-26 2019-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
JP7029445B2 (ja) 2016-09-02 2022-03-03 ブリストル-マイヤーズ スクイブ カンパニー 置換された三環式ヘテロ環化合物
US11059784B2 (en) 2017-08-09 2021-07-13 Bristol-Myers Squibb Company Oxime ether compounds
WO2019032632A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company ALKYLPHENYL COMPOUNDS
SG11202102062QA (en) 2018-09-18 2021-04-29 Shenzhen Whalehouse Tech Company Limited Movable dense storage and picking device, modular warehouse system and method for assembling the same
US20230151425A1 (en) 2020-03-11 2023-05-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
EP4395785A1 (en) 2021-08-31 2024-07-10 Inserm (Institut National de la Santé et de la Recherche Scientifique) Methods for the treatment of ocular rosacea
CN113679716B (zh) 2021-10-13 2024-03-26 史大永 溴酚-吡唑啉化合物在治疗猫冠状病毒疾病中的应用
CN114230457B (zh) * 2022-01-04 2023-06-09 中山大学 一类2-亚苄基四氢萘酮衍生物及其制备方法和应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1086068A (en) * 1964-09-02 1967-10-04 Ici Ltd Process for the whitening of polymeric materials and nitrogen-containing polycyclic compounds for use therein
BE789948A (fr) * 1971-10-13 1973-04-11 Sandoz Sa Nouveaux derives du pyrazole, leur preparation et leur application comme medicaments
US3816438A (en) * 1972-12-22 1974-06-11 Sandoz Ag 2h(1)-benzothiepino(5,4-c)-pyrazoles and(1)-benzothiopyrano(4,3-c)-pyrazoles
US3843666A (en) * 1973-05-29 1974-10-22 Sandoz Ag Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles
US4866025A (en) * 1988-09-30 1989-09-12 Eastman Kodak Company Thermally-transferable fluorescent diphenylpyrazolines
HUT67929A (en) * 1992-01-23 1995-05-29 Pfizer Benzopyran and related ltb4 antagonists
GB9318691D0 (en) 1993-09-09 1993-10-27 Merck Sharp & Dohme Therapeutic agents
ID16283A (id) 1996-03-20 1997-09-18 Astra Pharma Prod Senyawa yang berguna dibidang farmasi
AU711539B2 (en) * 1996-09-05 1999-10-14 Astra Pharmaceuticals Limited Novel aryl-pyridazines
JPH10273467A (ja) * 1997-01-29 1998-10-13 Snow Brand Milk Prod Co Ltd 新規テトラロン又はベンゾピラノン誘導体及びその製造方法
IT1292092B1 (it) 1997-06-05 1999-01-25 Geange Ltd Impiego di derivati eterociclici aromatici azotati nel trattamento topico di affezioni di tessuti epiteliali
WO1999055335A1 (en) 1998-04-30 1999-11-04 Basf Aktiengesellschaft Substituted tricyclic pyrazole derivatives with protein kinase activity
US6432974B1 (en) * 2000-02-04 2002-08-13 Wyeth Pyrrolo-isoquinoline and tetra-hydropyrrolo-isoquinoline derivatives and their use as mediators of the 5-HT7 receptor
WO2003079973A2 (en) 2002-03-08 2003-10-02 Merck & Co., Inc. Mitotic kinesin inhibitors
AU2003230581A1 (en) 2002-03-15 2003-09-29 Eli Lilly And Company Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
CN1319968C (zh) 2002-08-02 2007-06-06 沃泰克斯药物股份有限公司 用作gsk-3的抑制剂的吡唑组合物
ES2335099T3 (es) 2002-09-18 2010-03-22 Pfizer Products Inc. Novedosos compuestos de pirazol como inhibidor del factor de crecimiento transformante (tgf).
AU2004207740A1 (en) 2003-01-22 2004-08-12 Eli Lilly And Company Indole-derivative modulators of steroid hormone nuclear receptors
PL1697350T3 (pl) * 2003-12-19 2008-11-28 Lilly Co Eli Modulatory receptorów jądrowych dla tricyklicznych hormonów steroidowych
JP2007230869A (ja) 2004-04-05 2007-09-13 Takeda Chem Ind Ltd アルドステロン受容体拮抗剤
WO2006010142A2 (en) 2004-07-14 2006-01-26 Ligand Pharmaceuticals, Inc. Mineralocorticoid receptor modulator compounds, processes for their preparation, and their use
HUE041596T2 (hu) 2004-07-30 2019-05-28 Exelixis Inc Pirrol származékok mint gyógyászati szerek
US20110144128A1 (en) 2005-01-10 2011-06-16 Exelixis, Inc. Heterocyclic Carboxamide Compounds as Steroid Nuclear Receptors Ligands
US20100160304A1 (en) 2005-01-19 2010-06-24 Dainippon Sumitomo Pharma Co., Ltd Aromatic sulfone compound as aldosterone receptor modulator
JP2008530094A (ja) 2005-02-10 2008-08-07 メルク エンド カムパニー インコーポレーテッド 有糸***キネシン阻害剤

Also Published As

Publication number Publication date
ATE537151T1 (de) 2011-12-15
DK2089367T3 (da) 2012-02-06
RS52203B (en) 2012-10-31
MX2009004662A (es) 2009-05-22
AP2009004822A0 (en) 2009-04-30
RS20090208A (en) 2010-06-30
CU23779B7 (es) 2012-02-15
MY145795A (en) 2012-04-30
NO20091741L (no) 2009-05-29
NI200900071A (es) 2010-03-08
US7781428B2 (en) 2010-08-24
CU20090058A7 (es) 2011-07-11
CL2007003154A1 (es) 2008-05-09
MA30821B1 (fr) 2009-10-01
JP2010508257A (ja) 2010-03-18
IL198241A0 (en) 2009-12-24
CN101541757A (zh) 2009-09-23
UA92670C2 (ru) 2010-11-25
KR101107800B1 (ko) 2012-01-25
AU2007315884A1 (en) 2008-05-08
US20100280016A1 (en) 2010-11-04
KR20090060371A (ko) 2009-06-11
NZ575923A (en) 2011-01-28
TW200822924A (en) 2008-06-01
US20120035131A1 (en) 2012-02-09
CO6160307A2 (es) 2010-05-20
HRP20120078T1 (hr) 2012-02-29
SI2089367T1 (sl) 2012-02-29
TN2009000160A1 (fr) 2010-10-18
GEP20115239B (en) 2011-06-10
PL2089367T3 (pl) 2012-04-30
CY1112311T1 (el) 2015-12-09
US20080167294A1 (en) 2008-07-10
EA200970341A1 (ru) 2009-10-30
JP4977760B2 (ja) 2012-07-18
PE20081472A1 (es) 2008-10-18
AP2527A (en) 2012-12-06
BRPI0717937A2 (pt) 2013-12-03
EA016370B1 (ru) 2012-04-30
AU2007315884B2 (en) 2012-10-04
ES2375877T3 (es) 2012-03-07
AR063529A1 (es) 2009-01-28
HN2007000437A (es) 2011-01-17
EP2089367A1 (en) 2009-08-19
GT200700096A (es) 2010-07-15
PT2089367E (pt) 2012-02-01
CA2667966A1 (en) 2008-05-08
CR10725A (es) 2009-05-12
WO2008053300A1 (en) 2008-05-08
TWI357327B (en) 2012-02-01
EP2089367B1 (en) 2011-12-14
CA2667966C (en) 2011-08-02

Similar Documents

Publication Publication Date Title
UY30670A1 (es) Nuevos compuestos de pirazolina, composiciones conteniéndolos y aplicaciones.
UY31260A1 (es) Compuestos de pirazol, composiciones conteniendolos y aplicaciones.
CO6321276A2 (es) Derivados de tiazol usados como inhibidores de pi3- cinasa
UY30600A1 (es) Compuestos novedosos
PE20151781A1 (es) Piridonamidas como moduladores de canales de sodio
PE20152033A1 (es) Heterociclos bicicliclos como inhibidores de fgfr
PE20161405A1 (es) Analogos de cortistatina y sintesis y usos de los mismos
SV2011003855A (es) Heteroarilos sustituidos
ATE459622T1 (de) Tropanverbindungen
CR10027A (es) Nuevos derivados de pirrol fusionado
UY31750A (es) Compuestos y composiciones como inhibidores de quinasa
UY28756A1 (es) Compuestos
CR20120277A (es) Una forma cristalina y amorfa de genz 112638 hemitartrato como inhibidores de glucosilceramida sintasa
CR20110381A (es) Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2
UY31183A1 (es) Derivados de pirazinona y procesos para su preparación
HN2007000267A (es) Compuestos de 4-metil piridopirimidinoma
CR11653A (es) Nuevos derivados de carbazol inhibidores de hsp90, composiciones que los contienen y utilizacion
UY30856A1 (es) Nuevos derivados de 2,4 dianilinopirimidinas, su preparacion, como medicamentos, composiciones farmacéuticas y principalmente como inhibidores de ikk
CY1109766T1 (el) Παραγωγα αζαπεπτιδιου ως αναστολεις πρωτεασης hiv
UY32411A (es) DERIVADOS DE 4-AMINO-7,8-DIHIDROPIRIDO [4,3-d] PIRIMIDIN-5 (6H)-ONA
UY32553A (es) Nuevos derivados de la pirrolidinadiona espiroheterocíclicos 3-sustituidos
AR072726A1 (es) Derivados de indol macrociclicos utiles como inhibidores del virus de la hepatitis c
NI201100218A (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
UY32667A (es) Nuevos derivados de furano espiroheterocíclico y tiofuranodiona
UY32748A (es) 2-carboxamida-cicloamino-ureas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170728